FDA Adverse Event Injury Summary report: N

HANCOCK II AORTIC BIOPROSTHETIC HEART VALVE

MDR report key: 10041622 · Received May 10, 2020

Report

Report Number
2025587-2020-01602
Event Type
Injury
Date Received
May 10, 2020
Date of Event
October 22, 2019
Report Date
May 10, 2020
Manufacturer
MEDTRONIC HEART VALVES DIVISION
Product Code
DYE
PMA / PMN Number
P980043
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
PL
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

CITATION: HUDZIAK D ET AL. INFECTIOUS ENDOCARDITIS AFTER VALVE-IN-VALVE TRANSCATHETER AORTIC VALVE IMPLANTATION: REOPERATIVE TREATMENT OF INFECTIOUS ENDOCARDITIS. KARDIOLOGIA POLSKA. 2020; 78(1):84-85. DOI: 10.33963/KP.15029. EARLIEST DATE OF PUBLISH USED FOR EVENT DATE. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REGARDING A (B)(6)-YEAR-OLD MALE PATIENT WITH A MEDICAL HISTORY OF ATRIAL FIBRILLATION, CHRONIC RENAL INSUFFICIENCY, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ANEMIA, AND GASTROINTESTINAL TRACT BLEEDING WHO UNDERWENT IMPLANT OF A 23MM MEDTRONIC HANCOCK II BIOPROSTHETIC VALVE WITH A CONCOMITANT LEFT INTERNAL MAMMARY ARTERY GRAFT. NO SERIAL NUMBERS WERE PROVIDED. APPROXIMATELY 3 YEARS POST IMPLANT, A MEDTRONIC EVOLUT R TRANSCATHETER VALVE WAS IMPLANTED VALVE-IN-VALVE BECAUSE OF ELEVATED GRADIENTS (108MMHG MAXIMUM GRADIENT, 58MM MEAN GRADIENT). NO ADDITIONAL ADVERSE PATIENT EFFECTS OR PRODUCT PERFORMANCE ISSUES WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
505289 HANCOCK II AORTIC BIOPROSTHETIC HEART VALVE HEART-VALVE, REPLACEMENT DYE MEDTRONIC HEART VALVES DIVISION T505

Patients

Seq Age Sex Outcome Treatment
1 73 YR Required Intervention